YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.11 CNY | +0.43% |
|
+2.33% | +10.09% |
| Jun. 06 | Yuyue Medical Owners Prohibited from Leaving China for Alleged Links to Baiyao Corruption Case | MT |
| May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 1 M€ | -18.21% | - | |
| 1.32% | 2 M€ | -14.14% | ||
| 1.18% | 4 M€ | -2.96% | ||
| 0.13% | 35 M€ | -5.85% | - | |
| 0.11% | 2 M€ | +1.01% | - | |
| 0.10% | 4 M€ | -11.56% | ||
| 0.05% | 11 M€ | +4.31% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 152 M€ | +5.71% | - | |
| 0.01% | 451 M€ | +6.10% | - | |
| 0.01% | 2,838 M€ | +8.49% | - | |
| 0.01% | 114 M€ | +4.36% | - | |
| 0.00% | 35 M€ | +5.55% | - | |
| 0.00% | 7 M€ | +5.53% | - | |
| 0.00% | 32 M€ | +4.30% | - | |
| 0.00% | 36 M€ | +9.83% | - | |
| 0.00% | 414 M€ | +10.01% | - | |
| 0.00% | 40 M€ | +6.57% | - | |
| 0.00% | 324 M€ | +6.59% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-10
- Extraordinary Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
54.11
CNY
Average target price
65.01
CNY
Spread / Average Target
+20.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.09% | 13.32B | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd
